Imperial College London
Alternate

ProfessorNaomiChayen

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Prof Res Fellow - Professor of Biomedical Sciences
 
 
 
//

Contact

 

+44 (0)20 7594 3240n.chayen Website

 
 
//

Location

 

Office no. E304Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Adams:2017:10.1038/s41598-017-06642-w,
author = {Adams, GG and Alzahrani, Q and Jiwani, SI and Meal, A and Morgan, PS and Coffey, F and Kok, S and Rowe, AJ and Harding, SE and Chayen, N and Gillis, RB},
doi = {10.1038/s41598-017-06642-w},
journal = {Scientific Reports},
title = {Glargine and degludec: Solution behaviour of higher dose synthetic insulins.},
url = {http://dx.doi.org/10.1038/s41598-017-06642-w},
volume = {7},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Single, double and triple doses of the synthetic insulins glargine and degludec currently used in patient therapy are characterised using macromolecular hydrodynamic techniques (dynamic light scattering and analytical ultracentrifugation) in an attempt to provide the basis for improved personalised insulin profiling in patients with diabetes. Using dynamic light scattering and sedimentation velocity in the analytical ultracentrifuge glargine was shown to be primarily dimeric under solvent conditions used in current formulations whereas degludec behaved as a dihexamer with evidence of further association of the hexamers ("multi-hexamerisation"). Further analysis by sedimentation equilibrium showed that degludec exhibited reversible interaction between mono- and-di-hexamer forms. Unlike glargine, degludec showed strong thermodynamic non-ideality, but this was suppressed by the addition of salt. With such large injectable doses of synthetic insulins remaining in the physiological system for extended periods of time, in some case 24-40 hours, double and triple dose insulins may impact adversely on personalised insulin profiling in patients with diabetes.
AU  - Adams,GG
AU  - Alzahrani,Q
AU  - Jiwani,SI
AU  - Meal,A
AU  - Morgan,PS
AU  - Coffey,F
AU  - Kok,S
AU  - Rowe,AJ
AU  - Harding,SE
AU  - Chayen,N
AU  - Gillis,RB
DO  - 10.1038/s41598-017-06642-w
PY  - 2017///
SN  - 2045-2322
TI  - Glargine and degludec: Solution behaviour of higher dose synthetic insulins.
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-017-06642-w
UR  - http://www.ncbi.nlm.nih.gov/pubmed/28779138
UR  - http://hdl.handle.net/10044/1/49178
VL  - 7
ER  -
Download